Pfizer has modified the protocol for its late-stage study of its vaccine against the new coronavirus, this time to include more young participants. The company has received permission from the Food and Drug Administration to include adolescents aged 12 through 15 in its global COVID-19 vaccine study.
The company originally planned for 30,000 participants, but in September expanded that to 44,000 people. That increase was made to boost diversity in the trial population, specifically by including 16- and 17-year-old teens, as well as stable patients with some common chronic infections: hepatitis B, hepatitis C and HIV.
Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1883.75 |
| Dr. Reddys Lab | 1290.80 |
| Cipla | 1340.10 |
| Zydus Lifesciences | 943.70 |
| Lupin | 2250.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: